- 1 Defining Key Deprescribing Measures from Electronic Health Data: A Multisite Data
- 2 Harmonization Project

5

12

- 4 Short title: Deprescribing Measures from EHR Data
- 6 Authors: Sascha Dublin, MD, PhD^{a,b,c}, Ladia Albertson-Junkans, MPH^a, Thanh Phuong Pham
- 7 Nguyen, PharmD, MBA, MSCE^d, Juliessa M. Pavon, MD, MHS^{e,f}, Susan N. Hastings, MD,
- 8 MHS^{e,f,g}, Matthew L. Maciejewski, PhD^{e,g,h}, Allison Willis, MD, MS^d, Lindsay Zepel, MS^h, Sean
- 9 Hennessy, PharmD, PhD^d, Kathleen B. Albers, MPHⁱ, Danielle Mowery, PhD, MS^d, Amy G.
- 10 Clark, PhD^h, Sunil Thomas, MBA/TM^d, Michael A. Steinman, MD^{j,k}, Cynthia M. Boyd, MD,
- 11 MPH¹, Elizabeth A. Bayliss, MD, MSPH^{i,m}
- 13 Author Affiliations:
- ^aKaiser Permanente Washington Health Research Institute, Seattle, WA
- bUniversity of Washington Department of Epidemiology, Seattle, WA
- ^cKaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA
- d University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
- ^eDuke University School of Medicine, Durham, NC
- ^fDurham VA Healthcare System, Geriatrics Education Research and Clinical Centers
- ^gDurham VA Center of Innovation to Accelerate Discovery and Practice Transformation
- ^hDuke University, Department of Population Health Sciences
- ⁱKaiser Permanente Colorado Institute for Health Research, Aurora, CO
- ^jDivision of Geriatrics, University of California San Francisco, San Francisco, CO

^kSan Francisco Veterans Administration Medical Center, San Francisco, CA 24 25 ¹Division of Geriatric Medicine and Gerontology and Center for Transformative Geriatric 26 Research, Johns Hopkins University School of Medicine, Baltimore, MD 27 ^mDepartment of Family Medicine, University of Colorado School of Medicine, Aurora, CO 28 Corresponding author: Dr. Sascha Dublin, 1730 Minor Avenue, Suite 1600, Seattle, WA, 98101. 29 30 Email: Sascha.Dublin@kp.org. 31 Disclosures (all funding sources): This work was funded by National Institute on Aging grants 32 33 R24AG064025 and 1K23AG058788-03 (Pavon) and US Department of Veterans Affairs grant RCS 10-391 (Maciejewski). The contents do not represent the views of the U.S. Department of 34 Veterans Affairs or the United States Government. 35 36 Prior presentations: Portions of this paper were presented at the US Deprescribing Research 37 38 Network Annual Meeting in Long Beach, California in May 2023; at the International Conference on Pharmacoepidemiology in Halifax, Nova Scotia in August 2023; and at the 39 National Association of Primary Care Research Group annual meeting in San Francisco, 40 California in November 2023. 41 42 Word count: abstract 300 words, main text 1996 words 43 Tables/figures: 3 44 45 46 **Impact Statement:**

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

We certify that this work is novel. Prior papers have identified a need for greater standardization of definitions for medication exposure and discontinuation in deprescribing studies. To our knowledge, no prior paper has systematically examined the construction of deprescribing variables from electronic health data. This is the first paper to present standardized definitions for variables needed for deprescribing studies based on electronic health data, to implement these definitions in multiple healthcare systems and data types, and to examine their performance. This is also the first paper to examine the impact of using medication orders vs. dispensing data to define key deprescribing variables. **Key points:** Using benzodiazepines and Z-drugs as a case study, we developed and implemented standardized definitions for key variables needed for deprescribing studies using electronic health records data from 5 diverse U.S. healthcare systems. • Requiring a gap of ≥ 90 days without an active order/dispensing or, for a fixed time point, requiring a period of ≥30 days surrounding it with no order/dispensing will likely increase the accuracy of identifying true medication discontinuation. Applying definitions to medication orders data generated higher estimates of chronic use and lower estimates of medication discontinuation than dispensing data. Why does this paper matter? The use of standardized variable definitions in deprescribing studies will improve the ability to synthesize data and compare results between studies,

advancing knowledge and supporting more evidence-based guidelines for clinical care.

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

Abstract Background: Deprescribing, or systematically stopping or reducing risky or unneeded medications, could improve older adults' health. Electronic health records (EHR) hold promise for supporting deprescribing studies, but there are currently no standardized measures for key variables. With benzodiazepines and other sedative-hypnotics (Z-drugs) as a case study, we developed and examined EHR-based definitions for chronic medication use and discontinuation. **Methods:** We conducted a retrospective cohort study set within 5 U.S. healthcare systems. The study population was adults age 65+ from 2017-2019 with chronic benzodiazepine or Z-drug use, without dementia or serious mental illness. We used EHR data for medication orders and dispensings to define key variables, including chronic benzodiazepine/Z-drug use and discontinuation. We explored definitions for discontinuation based on 1) gaps in medication availability during follow-up (no active order/dispensing) or 2) not having medication available at a fixed time point. We examined the impact of varying gap length from 30 to 180 days, accounting for stockpiling, and requiring a 30-day period without orders/dispensings ("halo") around the fixed time point. We also compared results from medication orders vs. dispensings for the same population. **Results:** 1.6-2.6% of older adults had chronic use of a benzodiazepine or Z-drug. Depending on the definition and site, the proportion discontinuing use over 12 months ranged from 6% to 49%. Requiring a longer gap in orders/dispensings or a 30-day "halo" around a fixed time point resulted in lower estimates. Orders data were less likely to identify discontinuation than dispensing data. **Conclusions:** Requiring a medication gap of ≥ 90 days or a 30-day period with no

orders/dispensings around a fixed time point may improve the likelihood that an outcome

represents true discontinuation. Orders data appear to underestimate discontinuation compared to dispensing data. More work is needed to adapt and test the proposed definitions for other drug classes and care settings.

Keywords (3-5): deprescribing, measurement, electronic health records, benzodiazepines, medication discontinuation

Introduction

Polypharmacy is common in older adults and has been associated with many adverse outcomes.[1-4] A potential solution is deprescribing – systematically stopping or tapering medications that are risky or no longer needed, with ongoing monitoring.[5, 6] There are important gaps in the evidence about deprescribing, including its impact on health outcomes.

Electronic health records (EHR) data can support evidence generation, for instance by supporting efficient recruitment and outcome ascertainment for randomized controlled trials (RCTs). They can also be used for observational studies. Benefits include access to large and more representative populations.

Deprescribing studies have used heterogeneous definitions for key outcome variables, including chronic medication use and discontinuation, hindering comparison and synthesis of results.[7] EHR-based definitions for these variables have not been systematically proposed or examined. To address this gap, the US Deprescribing Research Network convened a workgroup to develop and implement standardized EHR-based definitions for key variables for deprescribing studies.

Methods

Overview

Researchers from 5 U.S. healthcare systems met regularly, selecting high-priority variables and collaboratively developing definitions that each site operationalized. We carried out a retrospective cohort study, identifying individuals with chronic medication use and following them to identify discontinuation. As a case study, we chose benzodiazepines and related sedative-hypnotics (zolpidem, eszopiclone, and zaleplon, or "Z-drugs"), common targets

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

for deprescribing. To provide a framework, we emulated some elements of D-PRESCRIBE, a community-based deprescribing RCT.[8] Study settings and data sources Participating healthcare systems (Appendix Table 1) included 2 integrated healthcare systems, regions of Kaiser Permanente (KP); two academic healthcare systems, the University of Pennsylvania and Duke University; and the Durham Veterans Affairs Health Care System (VAHCS). The first 4 use Epic EHRs. All systems have EHR data for demographic characteristics, visits, diagnoses, and medication orders. The KP regions also have claims data, including health plan enrollment and pharmacy dispensings. Medication orders come from the EHR and show prescriptions ordered by a clinician, while dispensing data are generated by pharmacies as part of filling these prescriptions. One academic site obtained dispensing data from a vendor, Surescripts, while the other had only orders data. **Study population** Inclusion and exclusion criteria were modeled after D-PRESCRIBE (see Appendix Table 2). We included people aged 65 and older who engaged with our healthcare systems from 2017-2019. We required chronic use of a benzodiazepine or Z-drug in 2018 (definitions follow). We excluded people with serious mental illness or significant cognitive impairment and those needing an interpreter. Defining chronic benzodiazepine or Z-drug use Table 1 provides definitions for key variables. We also provide a Programmers' Guide (Supplemental Appendix Text) with practical and technical guidance for implementing the definitions. Sites with dispensing data defined chronic benzodiazepine/Z-drug use as having ≥3 dispensings and \geq 45 days' supply within 100 days. The rationale for the days' supply

requirement is that a more stringent definition of chronic use will identify individuals at higher risk of harm and make it easier to ascertain discontinuation accurately. When using orders data to define chronic use, we required ≥3 orders within 100 days, counting the initial order and any refills included. Implicitly, these definitions assume that a typical dispensing/prescription is for ≤30 days' supply. The orders-based definition does not include a days' supply requirement because orders generally lack this element. When defining chronic use in 2018, we considered dispensings/orders from 2017 and 2018.

Individuals were assigned an "index date" which separated the baseline period, during which chronic use was assessed, from the follow-up period, during which discontinuation was assessed. In dispensing data, the index date was the date of the dispensing that qualified a person as having chronic use (i.e., the third dispensing or the dispensing that led to ≥45 total days' supply). It is challenging to assign an index date from orders data because people may qualify as having chronic use based on allowed refills, which do not have a set start date. Thus, for people meeting chronic use criteria in 2018 based on orders, we assigned 1/1/2019 as the index date.

Baseline characteristics

We extracted data about demographics, diagnoses, and medication use (Appendix Table 3). We ascertained opioid use because these medications are often used with benzodiazepines, and concomitant use increases the risk of adverse outcomes. Chronic opioid use was identified using the same definition as for benzodiazepines/Z-drugs.

We measured the number of chronic medications other than benzodiazepines/Z-drugs on the index date. First, we identified those where the index date fell within the medication's days' supply (using dispensing data) or on or between an order's start and end date. For dispensings, we included only those with \geq 28 days' supply. We excluded products that are not chronic

medications (e.g., vaccines). We then counted the number of distinct national drug codes for dispensing data or generic medication names (for orders).

Defining medication discontinuation

We took two conceptual approaches (Table 1): 1) determining whether a person had stopped use for a set *duration of time* at any point during a specified follow-up period ("gapbased" definition) and 2) determining whether the person had stopped using the medication at a *fixed time point* during follow-up. We followed individuals for 12 months after the index date.

For dispensings, a medication was considered "in use" from the dispensing date through the run-out date, defined as dispensing date + days' supply – 1 (assuming the first dose is taken on the dispensing date). If there was not another dispensing within 30 days after the run-out date, we considered this a 30-day gap. Similarly, we identified gaps of 60, 90, or 180 days. As a variation, we defined gaps accounting for medication stockpiling.

For orders, a medication was considered "in use" from the order start date through the end date. The order end date accounts for allowed refills (essentially, assuming all allowed refills were utilized). It can be retroactively modified by various events, such as the patient reporting that they stopped the medication.

For the fixed time point definition, we assessed whether a person appeared to have the medication on hand at a given time point (Appendix Figure 1a). If the time point did not fall within a period when the medication was in use, this was considered discontinuation. We defined discontinuation at days 90, 180, 270 and 365 of follow-up. We realized that for a person continuing use, a fixed time point could fall within a brief gap between two dispensings. Thus, as a variation, we required that the fixed time point fall within a 30-day period with no dispensings or orders ("halo"; see Appendix Figure 1b).

We created variables for discontinuation using the gap-based and fixed time point approaches and compared the results.

Comparing results from medication orders versus dispensings

Orders and dispensing data differ in important ways that could affect measurement.

Orders lack information about days' supply, and it is impossible to determine whether allowed refills were dispensed or when. The order end date is calculated assuming all refills were used, potentially overestimating use. We utilized data from KPWA, which has both orders and dispensing data, to define chronic benzodiazepine/Z-drug use and discontinuation using both data types for a set population and examined agreement.

Results

In 2018, the prevalence of chronic use of benzodiazepines/Z-drugs ranged from 1.5% to 2.6% across sites (Appendix Figure 2). Appendix Figures 3a-3f show the impact of inclusion and exclusion criteria. People with chronic benzodiazepine/Z-drug use had a mean age of 71.5-73.3 years, about two-thirds were female (except at the VAHCS), and most were white (Appendix Table 3). Between 31-66% had a diagnosis of anxiety in the EHR and 4-31% a diagnosis of insomnia.

Across sites, the proportion of people with a gap in use of \geq 30 days during follow-up varied from 13-49% and for gaps \geq 180 days, from 6-15% (Figure 1). As the gap length increased, the proportion discontinuing decreased. Site 5, which used orders data, had the lowest apparent discontinuation rates.

With the fixed time point definition, the proportion of individuals who discontinued benzodiazepine/Z-drug use ranged from 9-32% at 180 days after the index date and from 20-36% at 365 days (Figure 2). Requiring a 30-day "halo" with no order/dispensing around the fixed

point led to substantially lower estimates. Discontinuation rates were slightly lower after adjustment for stockpiling (Appendix Figure 4), but for longer gaps, this adjustment mattered less.

In an analysis of individuals at one site with both orders and dispensing data, far more people appeared to have chronic benzodiazepine/Z-drug use based on orders than dispensings (Appendix Table 4a). Of those with chronic use defined from orders, only 56% also qualified based on dispensings. The discrepancy was greatest among individuals who qualified based on a single order (Appendix Table 4b). Discontinuation rates derived from dispensings were substantially higher than from orders (Appendix Table 5); for example, at 180 days after index date, the discontinuation rate was 32% based on dispensings vs. 20% based on orders.

Discussion

We found that at 5 U.S. healthcare systems in 2018, 1.5-2.6% of older adults were using benzodiazepines or Z-drugs chronically. For comparison, a U.S. study using dispensing data found that in 2008, 2.7% of people aged 65-80 had long-term benzodiazepine use,[9] while in Canada in 2006, 3.5% of older adults had long-term use.[10]

This multisite investigation yielded three key insights. First, discontinuation rates over 12 months of follow-up ranged from 6 to 49% depending on the definition; requiring a longer gap to qualify as discontinuation resulted in a lower discontinuation rate. Our results suggest that gaps of 30 or 60 days may be less likely to represent true discontinuation than longer gaps. Second, when defining discontinuation at a fixed time point, requiring a 30-day "halo" period resulted in lower discontinuation rates. This indicates that many people received subsequent orders/fills shortly after the time point, suggesting they did not truly discontinue. Third, data from orders classified more people as having chronic use and identified fewer discontinuations than

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

dispensing data. Using orders data for this purpose poses challenges, including ambiguity about refill usage. Orders may remain active long after use has stopped. Thus, dispensing data are likely more precise for these purposes. This is the first paper to examine the construction of deprescribing variables from EHR data systematically. Our results align with some prior findings. Niznik et al. examined bisphosphonate discontinuation and recommended requiring longer gaps (≥90 days).[11] Another study compared definitions of opioid use from orders vs. dispensing data. They had orders data from a single healthcare system and found that dispensing data yielded higher opioid use estimates than orders (the reverse of our findings).[12] These results illustrate the challenges of using orders data, in this case the potential to underestimate use due to fragmentation of care. Strengths of this project include the involvement of 5 healthcare systems representing different U.S. regions, patient populations, and types of data. We examined several definitions for medication discontinuation and developed a programmers' guide (see Appendix). Benzodiazepines and Z-drugs are controlled substances and are the subject of many policies, guidelines and regulations. Some of these limit prescriptions to 30 days' supply[13], and at our sites most dispensings were for \leq 30 days. This influenced our algorithms. Other chronic medications are often prescribed with 90 days' supply, which may affect the transferability of our definitions. Also, benzodiazepines/Z-drugs are often used sporadically, making it harder to identify discontinuation compared to daily medications. We lacked a gold standard against which we could evaluate our definitions' performance. Our study did not investigate the reasons for discontinuation, so we could not distinguish between clinically recommended discontinuation and patient-driven discontinuation without clinical support.

Additional research is needed to understand the intent behind observed discontinuations and to develop EHR-based definitions for dose reduction or tapering. Our proposed definitions should be adapted and tested for other chronic medications and care settings.

In conclusion, it is feasible to develop and apply standardized, EHR-based definitions for deprescribing variables in diverse settings. When selecting variable definitions, researchers should consider the potential impacts of misclassification given their study design and aims. Our goal is to provide guidance for these decisions and to support greater standardization of measures, improving the evidence base for deprescribing.

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289 290 **Acknowledgments** Conflicts of interest: SD has received funding from GSK. SH has consulted for or received funding from Pfizer, Johnson & Johnson, Novo Nordisk, Arbor Pharmaceuticals, the Medullary Thyroid Cancer Consortium (Novo Nordisk, AstraZeneca, GlaxoSmithKline and Eli Lilly), Biogen, Intercept Pharmaceuticals, Provention Bio, bluebird bio, and Amylyx Pharmaceuticals. TPPN was a member of the 2022-2023 Junior Investigator Intensive Program of the US Deprescribing Research Network, which is funded by the National Institute on Aging, and has received support from Acadia Pharmaceuticals. MM owns stock in Amgen. Other authors have no conflicts to report. **Author Contributions:** Study concept and design: SD, LAJ, TPPN, JMP, SNH, MLM, AGC, SH, AW, KBA, DM, EAB Acquisition of data: LAJ, KBA, DM, LZ, ST Analysis and interpretation of data: all authors Preparation of manuscript: all authors Sponsor's Role: The sponsor did not play a role in study design, methods, data collection, analysis, or preparation of the manuscript.

References

291

- 292 1. Chang, T.I., et al., Polypharmacy, hospitalization, and mortality risk: a nationwide
- 293 *cohort study.* Sci Rep, 2020. **10**(1): p. 18964.
- 294 2. Laflamme, L., et al., Type, number or both? A population-based matched case-control
- study on the risk of fall injuries among older people and number of medications beyond
- 296 *fall-inducing drugs.* PLoS One, 2015. **10**(3): p. e0123390.
- 297 3. Leelakanok, N., et al., Association between polypharmacy and death: A systematic review
- and meta-analysis. J Am Pharm Assoc (2003), 2017. **57**(6): p. 729-738.e10.
- 299 4. Park, H.Y., et al., The Association between Polypharmacy and Hip Fracture in
- 300 Osteoporotic Women: A Nested Case-Control Study in South Korea. Clin Drug Investig,
- 301 2019. **39**(1): p. 63-71.
- 302 5. Woodward, M.C., Deprescribing: Achieving Better Health Outcomes for Older People
- through Reducing Medications. J Pharm Pract Res, 2003. **33**: p. 323-8.
- Thompson, W. and B. Farrell, *Deprescribing: what is it and what does the evidence tell*
- 305 *us?* Can J Hosp Pharm, 2013. **66**(3): p. 201-2.
- 306 7. Bayliss, E.A., et al., *Recommendations for outcome measurement for deprescribing*
- intervention studies. J Am Geriatr Soc, 2022. **70**(9): p. 2487-2497.
- 308 8. Martin, P., et al., Effect of a Pharmacist-Led Educational Intervention on Inappropriate
- 309 Medication Prescriptions in Older Adults: The D-PRESCRIBE Randomized Clinical
- 310 *Trial.* Jama, 2018. **320**(18): p. 1889-1898.
- Olfson, M., M. King, and M. Schoenbaum, *Benzodiazepine use in the United States*.
- JAMA Psychiatry, 2015. **72**(2): p. 136-42.

Cunningham, C.M., G.E. Hanley, and S. Morgan, Patterns in the use of benzodiazepines in British Columbia: examining the impact of increasing research and guideline cautions against long-term use. Health Policy, 2010. 97(2-3): p. 122-9.
 Niznik, J.D., et al., Patterns of oral bisphosphonate deprescribing in older nursing home residents with dementia. Osteoporos Int, 2022. 33(2): p. 379-390.
 Young, J.C., et al., Considerations for observational study design: Comparing the evidence of opioid use between electronic health records and insurance claims. Pharmacoepidemiol Drug Saf, 2022. 31(8): p. 913-920.
 Tennessee State Government. New Law Restricts Amount of Some Powerful Drugs That Can be Dispensed in Tennessee. 2013 October 11, 2013 [cited 2023 September 2].

Figure Legend

Figure 1. Prevalence of medication discontinuation during 12 months of follow-up across sites, using a gap-based definition and varying gap length.

Figure 2. Prevalence of medication discontinuation during 12 months of follow-up across sites, using the fixed time point definition. Estimates for Sites A-D are adjusted for stockpiling. Site E estimates are based on orders data and given challenges in measuring order end dates, there was no adjustment for stockpiling.

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

List of Supplemental Material for Online Publication Supplemental Appendix Text: Programmers' Guide. Provides detailed technical and practical guidance for working with orders and dispensing data to implement the definitions of deprescribing variables presented in this paper. Appendix Table 1: Descriptions of healthcare systems participating in Data Harmonization Workgroup Appendix Table 2: Definitions of inclusion and exclusion criteria and lists of diagnosis codes and medications Appendix Table 3: Characteristics of people aged 65 or older with chronic benzodiazepine or Zdrug use at 5 US healthcare systems Appendix Table 4a: Comparing chronic use defined from medication orders vs. dispensings for the same population Appendix Table 4b: Comparing chronic use defined from medication orders vs. dispensings, stratified by number of medication orders Appendix Table 5: Comparing measures of discontinuation defined from orders vs. dispensing data for the same population Appendix Figure 1a: Illustration of fixed time point definition of discontinuation, without halo Appendix Figure 1b: Illustration of fixed time point definition of discontinuation, with halo. In the top row, representing no discontinuation, there are dispensings or orders within the 30-day halo period around the fixed point. In the bottom line, representing discontinuation, there are no dispensings or orders within the 30-day halo period around the fixed point. Note: the 30-day

period does not have to be symmetric around the fixed point; it represents any 30-day period that contains the fixed point within it.

Appendix Figure 2. Prevalence of Benzodiazepine and Z-drug Use in People Aged ≥65 Within 5 U.S. Healthcare Systems, 2018.

Appendix Figures 3a-3f: Results of Applying Inclusion and Exclusion Criteria at Each Site Appendix Figure 4: Impact of Adjusting for Medication Stockpiling on Estimated Discontinuation Rates (Using Gap-Based Definition)

Table 1: Definitions for Deprescribing Measures*

Measure	Definition
Chronic benzodiazepine/	≥3 dispensings and a total of ≥45 days' supply within 100 days.
Z-drug use, from dispensing	
data	
Chronic benzodiazepine/	≥3 orders within 100 days, counting both the initial order and any
Z-drug use, from orders data	refills included.
Discontinuation:	For dispensing data: during 12 months of follow-up, the presence
Gap-based measure	of a period of X days after the run-out date of a dispensing
	without a subsequent dispensing. The "run-out date" was defined
	as the date of dispensing + days' supply -1.
	For orders data: during 12 months of follow-up, the presence of a
	period of X days following the end date of an order without a
	new medication order.
	In this study we examined gap lengths of 30, 60, 90 and 180 days.
Discontinuation:	For dispensing data: Discontinuation defined as present if the
Fixed time point measure	fixed time point of interest does not fall within a period when the
Trace time point measure	medication was "in use," that is, within the dispensed days'
	supply for a dispensing of the medication.
	supply for a disposioning of the medicalism
	For orders data: Discontinuation defined as present if the fixed
	time point does not fall within a time period when the medication
	is "in use," that is, on or between the start and end dates for an
	order for the medication.
	Fixed time points considered in this study: 90, 180, 270 and 365
	days after index date.
	As a variation, we explored the impact of also requiring a "halo"
	of 30 days around the fixed time point with no medication orders
Niverban of above ::	or dispensings.
Number of chronic medications used at baseline	Number of medications "in use" on the index date that had at
medications used at baseline	least 28 days' supply, excluding certain products that are not
	chronic medications (e.g., vaccines, allergenic extracts, toxoids,
	supplies such as glucose test strips, and others).

^{*}Please see the accompanying Programmers' Guide (Supplemental Appendix Text) for detailed practical and technical guidance about implementing the definitions.

